The Molecular Systems Pathology Core will provide expert morphological and molecular evaluation of normal and tumor samples of human and experimental models to investigators of this Program Project. It will investigate the potential clinical relevance of pathways and lead compounds identified from the preclinical models in the projects. The Core will assist in the generation and validation of data regarding genetic alterations associated with tumorigenesis and temporal maps of early versus late tumor progression. The Core will support the overall goals of the Program through the application of novel technologies in the areas of object-oriented image analysis and quantitative biomarker multiplexing, allowing for integration of phenotype- genotype, and providing patient-specific risk profiles. It will also participate in the integration of data between Projects, and especially between Core B (Levine) and our Core C. The Core has ample tissue resources and will assist all Projects. These include well-characterized cohorts of human hepatocellular carcinomas (HCC), breast carcinomas, lymphoma and leukemia cases, plus multiple tissue microarrays, all cases linked to outcome data. Tissue specimens will be provided for laboratory studies under strict guidelines.
The Specific Aims are: (1) To confirm histopathology and morphometric parameters of human tumors and murine models developed by all Projects. More specifically, well-characterized HCC cases will be use for the assessment of oncogenic gain of function of certain p53 mutants [Prives (Project 1) and Lowe (Project 4)]. (2) To develop and perform quantitative phenotypic assessment of in situ signaling pathways in the primary patient specimens and mouse models using multiplex immunofluorescence/multiplex immunohistochemistry combined with image analysis [e.g., Stockwell (Project 2) and Prives (Project 1) to determine and validate expression levels of biomarkers of ferroptosis and p53-regulated genes in mevalonic acid (MVA) pathway]. (3) To further enhance and conduct qualitative and quantitative microscopy assessment of heterochromatic marks to assist in the analysis of oncogene-induced chromatin transitions and DNA damage response (DDR) [e.g., Petrini (Project 3) analyses of pre- and post-oncogenic stresses with high resolution assays, such as ?H2AX, that allows quantification of foci in nuclei of cells of interest). (4) To characterize context dependencies of wild-type and mutant p53 effector programs, and p53-mediated gen repression in tumorigenesis and tumor maintenance [e.g., Lowe (Project4) pre- and post-treated analyses of transgenic mice with B cell lymphomas). (5) To explore the relationship between p53 activities, mutational loss and cancer stem cells from certain solid tumors; and assist in the analysis of p53 in regulating Ras-induced p53 senescence (Lowe and Levin).
This Core innovatively supports the Program Project because it provides a centralized, standardized and independent pathology assessment of all tissues that improves objectivity and permits the PIs to make conclusions. In addition, the Core promotes outstanding translational research on molecular mechanisms of disease initiation and progression by providing technical and tissue resources aimed at characterizing genetic aberrations and altered expression levels of genes involved in such processes. Critical to this program, and to the scientific community, is the generation/characterization of new antibodies/molecular probes and implementation of novel techniques to evaluate pathways of relevance through innovative developments in tissue morphometry and quantitative biomarker multiplexing. Dr. Cordon-Cardo has been the Core PI for the past 15 years, and is a regular participant in the program meetings, providing the research group the opportunity to match research and patient needs with the Core.
| Morris, Dylan H; Gostic, Katelyn M; Pompei, Simone et al. (2018) Predictive Modeling of Influenza Shows the Promise of Applied Evolutionary Biology. Trends Microbiol 26:102-118 |
| Solovyov, Alexander; Vabret, Nicolas; Arora, Kshitij S et al. (2018) Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes. Cell Rep 23:512-521 |
| Gaschler, Michael M; Hu, Fanghao; Feng, Huizhong et al. (2018) Determination of the Subcellular Localization and Mechanism of Action of Ferrostatins in Suppressing Ferroptosis. ACS Chem Biol 13:1013-1020 |
| Rokudai, Susumu; Li, Yingchun; Otaka, Yukihiro et al. (2018) STXBP4 regulates APC/C-mediated p63 turnover and drives squamous cell carcinogenesis. Proc Natl Acad Sci U S A 115:E4806-E4814 |
| Rastogi, Chaitanya; Rube, H Tomas; Kribelbauer, Judith F et al. (2018) Accurate and sensitive quantification of protein-DNA binding affinity. Proc Natl Acad Sci U S A 115:E3692-E3701 |
| Baugh, Evan H; Ke, Hua; Levine, Arnold J et al. (2018) Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ 25:154-160 |
| Agmon, Eran; Solon, Jérôme; Bassereau, Patricia et al. (2018) Modeling the effects of lipid peroxidation during ferroptosis on membrane properties. Sci Rep 8:5155 |
| Yozwiak, Carrie E; Hirschhorn, Tal; Stockwell, Brent R (2018) Toward a Microparticle-Based System for Pooled Assays of Small Molecules in Cellular Contexts. ACS Chem Biol 13:761-771 |
| Hirschhorn, Tal; Stockwell, Brent R (2018) The development of the concept of ferroptosis. Free Radic Biol Med : |
| Liu, Hengrui; Schreiber, Stuart L; Stockwell, Brent R (2018) Targeting Dependency on the GPX4 Lipid Peroxide Repair Pathway for Cancer Therapy. Biochemistry 57:2059-2060 |
Showing the most recent 10 out of 159 publications
